Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Addex Therapeutics Ltd
  6. News
  7. Summary
    ADXN   CH0029850754


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Addex Therapeutics : First patients enrolled into multi-center U.S. study (Form 6-K)

06/07/2021 | 06:09am EDT

First patientsenrolled intomulti-center U.S. study

Geneva, Switzerland, June 7,2021 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced that the first patients have been enrolled into a Phase 2 clinical study evaluating JNJ-40411813 (ADX71149) in patients with epilepsy. JNJ-40411813 (ADX71149) is a selective metabotropic glutamate type 2 (mGlu2) receptor positive allosteric modulator (PAM). The trial is being conducted in collaboration with Janssen Pharmaceuticals, Inc., part of the Janssen Pharmaceutical Companies of Johnson & Johnson.

'Addex is anticipating multiple clinical study catalysts during 2021. The first, starting with this epilepsy study, illustrates the continued commitment of our long-time collaboration partner Janssen Pharmaceuticals, Inc. to this program and to pioneering novel ways to help epilepsy patients. Data from the study are expected in Q3 2022,' said Tim Dyer, CEO of Addex. 'The start of additional clinical trials, including our pivotal study for our lead program dipraglurant in Parkinson's disease patients suffering from dyskinesia remains on track for this quarter.'

The multi-center study (ClinicalTrials.gov Identifier: NCT04836559) will assess the efficacy, safety, tolerability and pharmacokinetics of adjunctive JNJ-40411813 (ADX71149) administration in patients with focal onset seizures with suboptimal response to levetiracetam. The primary objective of the study is to evaluate the efficacy of JNJ-40411813 (ADX71149) in combination with levetiracetam using a time-to-event endpoint.

About the Collaboration
Under the research collaboration and license agreement, Addex granted Janssen Pharmaceuticals, Inc. an exclusive worldwide license to develop and commercialize mGlu2 PAM compounds. Addex is eligible for up to a total of €109 million in success-based development and regulatory milestone payments. In addition, Addex is eligible for low double-digit royalties on net sales of compounds developed under the agreement.

Glutamate mGlu2 Receptors and Epilepsy
Glutamate is the primary excitatory neurotransmitter in the brain and plays a key role in the initiation and spread of seizures. When activated, the mGlu2 receptor decreases the release of glutamate and consequently helps to maintain neurotransmitter balance. In the presence of agonist-induced activation, positive allosteric modulation of mGlu2 receptors could result in the normalization of the excessive glutamate release seen during a seizure. There is still an urgent need for more effective treatments for epilepsy, with improved tolerability and safety. JNJ-40411813 (ADX71149) was described in the Eilat 15 conference summary review as one of the most promising novel approaches currently in development (Bialer et al., 2020. Epilepsia). Proof of concept data with JNJ-40411813 (ADX71149) and other mGlu2 PAMs in animal models of epilepsy have been published in peer-reviewed journals (Metcalf et al., 2017 and 2018. Epilepsia).

About Addex Therapeutics

Addex Therapeutics is a clinical-stage pharmaceutical company focused on the development and commercialization of an emerging class of novel orally available small molecule drugs known as allosteric modulators for neurological disorders. Allosteric modulators offer several potential advantages over conventional non-allosteric molecules and may offer an improved therapeutic approach to conventional 'orthosteric' small molecule or biological drugs. Addex's allosteric modulator drug discovery platform targets receptors and other proteins that are recognized as essential for therapeutic intervention. Addex's lead product candidate, dipraglurant (mGlu5 negative allosteric modulator or NAM), is poised to start a pivotal registration clinical trial for Parkinson's disease levodopa induced dyskinesia (PD-LID) in Q2 2021. Addex is also investigating dipraglurant's therapeutic use in blepharospasm (a type of dystonia), for which a clinical trial is expected to be initiated in Q2 2021. Addex's GABAB PAM program has been licensed to Indivior PLC, which is focused on development for the treatment of addiction. Preclinical programs include GABAB PAM for CMT1A, mGlu7 NAM for PTSD, mGlu2 NAM for mild neurocognitive disorders, mGlu4 PAM for Parkinson's disease and mGlu3 PAM for neurodegenerative disorders. Addex shares are listed on the SIX Swiss Exchange and American Depositary Shares representing its shares are listed on the NASDAQ Capital Market, and trade under the ticker symbol 'ADXN' on each exchange.


Tim Dyer
Chief Executive Officer
Telephone: +41 22 884 15 55
Mike Sinclair
Partner, Halsin Partners
+44 7968 022075
James Carbonara
Hayden IR

Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including in respect of the anticipated initiation and progress of clinical trials and preclinical studies, and its future financing activities. The words 'may,' 'will,' 'could,' 'would,' 'should,' 'expect,' 'plan,' 'anticipate,' 'intend,' 'believe,' 'estimate,' 'predict,' 'project,' 'potential,' 'continue,' 'target' and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release, are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, uncertainties related to market conditions. These and other risks and uncertainties are described in the Company's Annual Report on Form 20-F filed with the SEC on March 11, 2021, as well as market conditions and regulatory review.

Any forward-looking statements contained in this press release represent Addex Therapeutics' views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Addex Therapeutics explicitly disclaims any obligation to update any forward-looking statements, except as required by law.


Addex Therapeutics Ltd. published this content on 07 June 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 07 June 2021 10:08:01 UTC.

ę Publicnow 2021
08/02ADDEX THERAPEUTICS : Appoints Seasoned Pharma Drug Researcher Mikhail Kalinichev..
08/02ADDEX THERAPEUTICS : to Release Half-Year 2021 Financial Results and Host Confer..
08/02PRESS RELEASE : Addex Appoints Seasoned Pharma Drug Researcher Mikhail Kaliniche..
08/02Addex Appoints Seasoned Pharma Drug Researcher Mikhail Kalinichev as Head of ..
08/02PRESS RELEASE : Addex Therapeutics to Release Half-Year 2021 Financial Results a..
08/02Addex Therapeutics Ltd Appoints Mikhail Kalinichev as Head of Translational S..
07/29ADDEX THERAPEUTICS : and Indivior Extend Research Collaboration on GABAB Positiv..
07/29PRESS RELEASE : Addex and Indivior Extend Research Collaboration on GABAB Positi..
07/29ADDEX THERAPEUTICS : and Indivior Extend Research Collaboration on GABAB Positiv..
07/29Addex Therapeutics and Indivior Extend Research Collaboration on Gabab Positi..
More news
Sales 2021 1,61 M 1,78 M 1,78 M
Net income 2021 -15,1 M -16,7 M -16,7 M
Net Debt 2021 5,28 M 5,84 M 5,84 M
P/E ratio 2021 -3,55x
Yield 2021 -
Capitalization 66,5 M 73,5 M 73,6 M
EV / Sales 2021 44,6x
EV / Sales 2022 98,8x
Nbr of Employees 27
Free-Float 80,5%
Duration : Period :
Addex Therapeutics Ltd Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ADDEX THERAPEUTICS LTD
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 2
Last Close Price 1,53 
Average target price
Spread / Average Target -
EPS Revisions
Managers and Directors
Timothy Dyer Chief Executive Officer & Director
LÚnaic TeyssÚdou Head-Finance
Vincent M. Lawton Chairman
Roger G. Mills Director & Chief Medical Officer
Raymond George Hill Director
Sector and Competitors
1st jan.Capi. (M$)
MODERNA, INC.231.78%139 174
LONZA GROUP AG25.60%58 688
CELLTRION, INC.-26.60%31 285
SEAGEN INC.-11.93%28 062